Results 81 to 90 of about 28,689 (318)

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib

Infection and Drug Resistance, 2020
Emiko Sakiyama, Yoshiaki Chinen, Taku Tsukamoto, Tomoko Takimoto-Shimomura, Saeko Kuwahara-Ota, Yayoi Matsumura-Kimoto, Yuji Shimura, Tsutomu Kobayashi, Shigeo Horiike, Junya Kuroda Division of Hematology and Oncology, Department of Medicine, Kyoto ...
Sakiyama E, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Kuwahara-Ota S, Matsumura-Kimoto Y, Shimura Y, Kobayashi T, Horiike S, Kuroda J   +9 more
doaj  

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor

Therapeutics and Clinical Risk Management, 2017
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm classified according to the 2016 revision of World Health Organization Classification of Tumors and Haematopoietic and Lymphoid Tissue. Ruxolitinib is an oral inhibitor of Janus kinase approved in the USA for the treatment of intermediate or high-risk PMF and approved in Europe for the ...
openaire   +5 more sources

Ruxolitinib therapy and telomere length in myelofibrosis [PDF]

Blood Cancer Journal, 2016
Telomeres are specialized structures of repetitive nucleotide sequences that cap the ends of human chromosomes. Their main purpose is to maintain genome stability and integrity, and to protect the cell from progressive DNA shortening during repeated division.
CAOCCI, GIOVANNI, GRECO, MARIANNA, Delogu, G, Secchi, C, Perra, A, GHIANI, STEFANIA, Orru, F, Vacca, A, Galimi, F, LA NASA, GIORGIO   +9 more
openaire   +5 more sources

Predicting OCT2/MATEs‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)

Clinical Pharmacology &Therapeutics, EarlyView.
Organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) transporters play significant roles in the renal secretion of organic cations and drug–drug interactions (DDIs). Recent in vitro studies indicate that the Ki values for OCT2 exhibit substrate dependency and increase in potency with pre‐incubation.
Satoshi Asano, Aleksandra Galetin, Yoshiko Tomita, Kathleen M. Giacomini, Xiaoyan Chu, Xinning Yang, Toshimichi Nakamura, Hiroyuki Kusuhara, Yuichi Sugiyama   +8 more
wiley   +1 more source

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

Haematologica, 2013
COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk myelofibrosis.
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson-Viitanen, William Sun, Victor Sandor, Hagop M. Kantarjian   +22 more
doaj   +1 more source

MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling. [PDF]

, 2015
Work in the Green lab is supported by Leukemia and Lymphoma Research, Cancer Research UK, the NIHR Cambridge Biomedical Research Centre, the Cambridge Experimental Cancer Medicine Centre, and the Leukemia and Lymphoma Society of America.
A Tefferi, A Tefferi, Claire N. Harrison, E Puigdecanet, F Passamonti, H Yoshida, J Nangalia, John T. Reilly, M Michalak, M Wictome, P Guglielmelli, R Rampal, S Schwemmers, S Verstovsek, S Verstovsek, T Klampfl   +15 more
core   +1 more source

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu, Hui Shen, Jonathan Greenbaum, Qiao‐Rong Yi, Shuang Liang, Yue Zhang, Jia‐Chen Liu, Chuan Qiu, Lan‐Juan Zhao, Qing Tian, Kuan‐Jui Su, Zhe Luo, Li Wu, Xiang‐He Meng, Hong‐Mei Xiao, Yun Deng, Yang Li, Dragana Lovre, Vivian Fonseca, Fernando L. Sanchez, Li‐Jun Tan, Hong‐Wen Deng   +21 more
wiley   +1 more source

Platelets as mediators of Thromboinflammation in chronic Myeloproliferative Neoplasms [PDF]

, 2019
Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood cell counts.
Heller, Paula Graciela, Marin Oyarzún, Cecilia Paola   +1 more
core   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms [PDF]

, 2015
Myeloproliferative neoplasms (MPN) are a diverse group of chronic hematological disorders that involve unregulated clonal proliferation of white blood cells.
Kapur, Reuben, Pandey, Ruchi
core   +1 more source